$CRIS News
Last published 5h ago
- 5h agoCRISCuris Provides Third Quarter 2026 Business UpdatePR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
- 3w agoCRISCuris, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional InvestorsPR NewswireLEXINGTON, Mass., Oct. 16, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available,
- 3mo agoCRISCuris, Inc. Announces Pricing of $5.6 Million Public OfferingPR NewswireLEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today
- 3mo agoCRISCuris Doses First Five Patients in TakeAim CLL StudyPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 3mo agoCRISCuris Announces Positive Emavusertib UpdatePR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 4mo agoCRISCuris Consents First Six Patients in TakeAim CLL StudyPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 4mo agoCRISCuris Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock SplitPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 6mo agoCRISCuris Provides First Quarter 2026 Business UpdatePR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 6mo agoCRISCuris to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 7mo agoCRISCuris Provides Fourth Quarter 2025 Business UpdatePR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 8mo agoCRISCuris to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 10mo agoCRISCuris Announces Closing of Private Placement Totaling up to $80.8 Million in Gross ProceedsPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 10mo agoCRISCuris Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross ProceedsPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 11mo agoCRISCuris Provides Updated Data from its Frontline AML Triplet StudyPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 12mo agoCRISCuris to Present at Upcoming 30th Annual SNO MeetingPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris Provides Third Quarter 2025 Business UpdatePR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris, Inc. (CRIS) Presents At Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoCRISCuris, Inc. (CRIS) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptEarnings Call Transcripts
- 1y agoCRISCuris to Present at Upcoming Healthcare Conferences in SeptemberPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris, Inc. (CRIS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCRISCuris Provides Second Quarter 2025 Business UpdatePR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris Announces $7.0 Million Registered Direct and Concurrent Private PlacementPR NewswireCuris, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small...
- 1y agoCRISCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris Provides First Quarter 2025 Business UpdatePR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris to Present at Upcoming Healthcare Conference in AprilPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris Provides Fourth Quarter 2024 Business UpdatePR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 1y agoCRISCuris Announces Additional Data from TakeAim Leukemia StudyPR NewswireCuris, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small...
- 1y agoCRISCuris, Inc. (CRIS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCRISCuris Provides Third Quarter 2024 Business UpdatePR NewswireCuris, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small...
- 2y agoCRISCuris to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris Announces $12.1 Million Registered Direct and Concurrent Private PlacementPR NewswireCuris, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small...
- 2y agoCRISCuris Announces the 3rd Annual Symposium on IRAK4 in CancerPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare ConferencePR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris to Present at Upcoming Healthcare Conferences in SeptemberPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris, Inc. (CRIS) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCRISCuris Provides Second Quarter 2024 Financial and Operating UpdatePR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris to Present at Upcoming Healthcare Conference in JulyPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris Announces Additional Data from TakeAim Leukemia StudyPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris to Present Updated Data from the TakeAim Leukemia StudyPR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris, Inc. (CRIS) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCRISCuris Provides First Quarter 2024 Business UpdatePR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
- 2y agoCRISCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswireCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...